Skip to main content
. 2023 Jul 5;29(4):987–1001. doi: 10.3350/cmh.2023.0035

Figure 2.

Figure 2.

Prevalence of visceral fat obesity (VFO), sarcopenia, and myosteatosisin controls and non-alcoholic fatty liver disease (NAFLD) without obesity in men and women. Asterisk (*) denotes the comparison between controls and NAFLD without obesity (*P<0.001 by chi-squared test).